CANCER

Immunology

Stem Cells

Cell Death

Neurodegeneration

Cellular Stress

Inflammation

Proteasome

Diabetes

View All Physiological Processes & Diseases

Acute inflammation is an immune response to a pathogen, irritant, or injury to remove whatever has caused the response, dispose of damaged tissue, and initiate healing. Resident immune cells at the site of insult recognize pathogen-associated molecular patterns (PAMPS) or damage-associated molecular patterns (DAMPS) and release various inflammatory mediators. Initial responses include vasodilation, increased vascular permeability, and extravasation of leukocytes. Mediators of inflammation include bradykinins, the complement system, cytokines, chemokines, leukotrienes, and prostaglandins among others. Chronic inflammation is characterized by infiltration of the tissue site by macrophages and lymphocytes leading to overall tissue damage. Chronic inflammatory diseases include diabetes, cardiovascular diseases, arthritis, allergies, cancer, and chronic obstructive pulmonary disease.

Home >> Inflammation

Inflammasome

MCC-950

MCC-950 is an inhibitor of the NLRP3 and AIM2 inflammasome

OLT1177

OLT1177 is a potent and specific inhibitor of the NLRP3 inflammasome

Talabostat mesylate

Non-selective inhibitor of S9 family proteases that activates the NLRP1B inflammasome

COX

Rofecoxib

Rofecoxib is a potent and selective COX-2 inhibitor

Oxaprozin

Clinically useful non-selective COX inhibitor

Celecoxib

Celecoxib is a potent and selective COX-2 inhibitor

NF-kB

Rocaglamide

Rocaglamide is a potent inhibitor of NF-κB activation

Helenalin

Potent natural product inhibitor of NF-κB

DMAPT

Parthenolide derivative that inhibits NF-κB

Lipoxygenase

Zileuton

Zileuton is a reversible inhibitor of 5-lipoxygenase

MK-866

MK-866 blocks leukotriene biosynthesis via inhibition of FLAP

NEW PRODUCTS

BIOCHEMICAL TARGETS

PROCESSES AND DISEASES

CUSTOM SYNTHESIS

CHEMICAL LIBRARIES

Update on the Latest Anti-SARS-CoV-2 Molecules

The emergence of SARS-CoV-2 has precipitated an unprecedented effort by the scientific community to find and develop potential therapeutics and...

REV-ERB agonists and Cancer

Researchers at the Salk Institute, the University of California, and the University of Texas have identified a potential new class of cancer...

SHP099 targets ALK inhibitor resistant cancer

Multiple cellular pathways can lead to acquired resistance to ALK inhibitors.  A common pathway is activation of alternate kinase pathways,...

Focus BiomoleculesPlymouth Meeting, PA USA1-855-FOCUS21

®Copyright 2021 Focus Biomolecules. All Rights Reserved. Site by A.N. Creative